It is thus reasonable to speculate that TET2 (and DNMT3A) mutations cooperate with EBV for DLBCL development, irrespectively of whether it is de novo or associated with AITL. This evidence concerns the gene TET2 and angioimmunoblastic T-cell lymphoma.